Orderly Post-IPO Gains

Iambic Therapeutics holds most of its debut pop as investors accept the valuation and focus on the company’s AI-designed oncology pipeline. The most likely path is a modest continuation or consolidation rather than another large one-day move, because the IPO was successful but still represents a single early-stage biotech listing.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.